BioVaxys adquiere la propiedad intelectual, la tecnología y los activos de la antigua IMV Inc.

Posted on by

BioVaxys adquiere toda la propiedad intelectual, la tecnología de plataforma inmunoterapéutica y los activos en etapa clínica de la antigua IMV Inc. VANCOUVER, BC, 13 de febrero de 2024 /PRNewswire/ — BioVaxys Technology Corp. (CSE: BIOV) (FRA: 5LB) (OTCQB: BVAXF) (“BioVaxys” o “la…

Posted in UncategorizedTagged
Powered by  GDPR Cookie Compliance
Privacy Overview

This website uses cookies so that we can provide you with the best user experience possible. Cookie information is stored in your browser and performs functions such as recognising you when you return to our website and helping our team to understand which sections of the website you find most interesting and useful.